TWO SIGMA INVESTMENTS, LP - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.

Quarter-by-quarter ownership
TWO SIGMA INVESTMENTS, LP ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$12,433,507
+32.6%
1,756,145
+31.9%
0.03%
+37.5%
Q2 2023$9,373,676
-16.1%
1,331,488
-0.7%
0.02%
-25.0%
Q1 2023$11,178,252
+89.5%
1,340,318
+160.8%
0.03%
+68.4%
Q4 2022$5,899,652
-54.6%
513,907
-50.2%
0.02%
-56.8%
Q3 2022$12,993,000
+406.4%
1,031,159
+325.1%
0.04%
+450.0%
Q2 2022$2,566,000
-20.8%
242,541
+21.8%
0.01%
-20.0%
Q1 2022$3,238,000
-80.9%
199,124
-83.7%
0.01%
-72.2%
Q4 2021$16,941,000
-48.0%
1,223,189
-46.1%
0.04%
-50.7%
Q3 2021$32,586,000
+11.4%
2,267,645
+22.5%
0.07%
+10.6%
Q2 2021$29,256,000
+4825.3%
1,850,485
+3070.3%
0.07%
+3200.0%
Q1 2021$594,000
-92.6%
58,369
-94.6%
0.00%
-91.3%
Q4 2020$7,997,000
+18.5%
1,073,416
-45.4%
0.02%
-4.2%
Q3 2020$6,751,000
-50.5%
1,965,439
-31.4%
0.02%
-64.7%
Q2 2020$13,644,000
+502.9%
2,863,381
+153.1%
0.07%
+277.8%
Q1 2020$2,263,000
-54.0%
1,131,521
-20.6%
0.02%
+20.0%
Q4 2019$4,918,000
+126.3%
1,425,455
+88.0%
0.02%
+114.3%
Q3 2019$2,173,000
+1.3%
758,399
+34.0%
0.01%0.0%
Q2 2019$2,146,000
-3.6%
566,169
+106.9%
0.01%0.0%
Q1 2019$2,227,000
+1435.9%
273,608
+1420.0%
0.01%
+600.0%
Q4 2018$145,000
-87.2%
18,000
-87.9%
0.00%
-66.7%
Q3 2018$1,134,000
+39.5%
148,649
+4.8%
0.00%
+50.0%
Q2 2018$813,000
+220.1%
141,821
+166.6%
0.00%
+100.0%
Q1 2018$254,000
-82.3%
53,200
-81.7%
0.00%
-80.0%
Q4 2017$1,431,000
+161.1%
291,428
+178.8%
0.01%
+150.0%
Q3 2017$548,000
-71.1%
104,547
-69.3%
0.00%
-71.4%
Q2 2017$1,896,000
-50.7%
341,013
-25.5%
0.01%
-46.2%
Q1 2017$3,844,000
+1407.5%
457,647
+1035.4%
0.01%
+1200.0%
Q4 2016$255,000
-92.2%
40,308
-84.4%
0.00%
-93.3%
Q2 2014$3,288,000
+1070.1%
257,889
+596.2%
0.02%
+650.0%
Q4 2013$281,000
-69.1%
37,043
-70.3%
0.00%
-66.7%
Q3 2013$908,000124,6560.01%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2020
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders